Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2(+)HR(+) breast cancer

Recent evidences from clinical trials (NCT04486911) revealed that the combination of pyrotinib, letrozole, and dalpiciclib exerted optimistic therapeutic effect in treating HER2(+)HR(+) breast cancer; however, the underlying molecular mechanism remained elusive. Through the drug sensitivity test, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Jiawen, Zhang, Yixiao, Niu, Nan, Bi, Kewei, Sun, Lisha, Qiao, Xinbo, Wang, Yimin, Zhang, Yinan, Jiang, Xiaofan, Wang, Dan, Ma, Qingtian, Li, Huajun, Liu, Caigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822241/
https://www.ncbi.nlm.nih.gov/pubmed/36602226
http://dx.doi.org/10.7554/eLife.85246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822241/
https://www.ncbi.nlm.nih.gov/pubmed/36602226
http://dx.doi.org/10.7554/eLife.85246

Ejemplares similares